Key result
Endovascular thrombectomy for managing renal cell carcinoma tumor thrombus in four patients resulted in no surgical complications and an average length of stay of 5.5 days.
Why the study?
Resection of renal cell carcinoma tumor thrombus extending into the IVC and heart often requires cardiopulmonary bypass and deep hypothermic circulatory arrest, which is not feasible for all patients.
Does a minimally invasive endovascular thrombectomy approach improve procedural outcomes in patients with renal cell carcinoma tumor thrombus invading the IVC or heart?
Case Report (n=4)
Does a minimally invasive endovascular thrombectomy approach improve procedural outcomes in patients with renal cell carcinoma tumor thrombus invading the IVC or heart?
Endovascular thrombectomy offers a feasible, minimally invasive alternative to cardiopulmonary bypass for managing advanced renal cell carcinoma with IVC or cardiac tumor thrombus.
May offer less invasive option for CPB-ineligible patients; hypothesis-generating and requires prospective validation.
BACKGROUND: Renal cell carcinoma tends to invade venous structures, frequently extending beyond the inferior vena cava and into the heart itself, such as into the right atrium or right ventricle. Resection of tumor burden, particularly tumor thrombus, often requires cardiopulmonary bypass (CPB) and deep hypothermic circulatory arrest (DHCA), which is not feasible for all patients. METHODS: Described in this study is a novel, minimally invasive endovascular approach involving endovascular thrombectomy as a viable approach in these select patients. RESULTS: There were no surgical complications, shorter operating times, less blood loss and an average length of stay of 5.5 days in the four patients undergoing this procedure. CONCLUSIONS: We demonstrate that this technique can eliminate the need for cardiac bypass and deep hypothermic cardiac arrest and its associated risks, thereby making surgery safer and more accessible for patients with advanced kidney cancers with an inferior vena cava tumor thrombus. Furthermore, it allows for this life-saving surgery to be carried out in medical centers or hospitals where cardiac surgery is unavailable, or when cardiopulmonary bypass is medically contraindicated.
No takes yet. Share an insight, caveat, or question.
Libertino et al. (2025) conducted a case report in Renal cell carcinoma with tumor thrombus (n=4). Endovascular thrombectomy was evaluated on Surgical complications and length of stay. Endovascular thrombectomy for managing renal cell carcinoma tumor thrombus in four patients resulted in no surgical complications and an average length of stay of 5.5 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: